An understanding of pattern recognition receptors (PRRs) and immunomodulatory approach based on activation of these receptors has provided insights critical for the management of neurological health disorders. Toll-like receptors (TLRs) are one of the most widely explored PRRs and have been exploited in the recent past for development of novel immunomodulatory therapeutic agents. Glioblastoma multiforme is characterized by significant infiltration of resident microglia and expresses all the members of the TLR family. The present report is focused on exciting findings pertaining to probable implications of TLR9 activation by unmethylated CG sequences for novel therapeutic intervention against glioblastoma multiforme, which could be a discrete step toward the effective management of neurological health issues.

对模式识别受体 (PRR) 和基于这些受体激活的免疫调节方法的理解为管理神经系统疾病提供了至关重要的见解。Toll 样受体 (TLR) 是研究最广泛的 PRR 之一，最近已被用于开发新型免疫调节治疗剂。多形性胶质母细胞瘤的特征在于常驻小胶质细胞的显着浸润，并表达 TLR 家族的所有成员。本报告的重点是关于未甲基化 CG 序列激活 TLR9 对多形性胶质母细胞瘤的新型治疗干预的可能影响的令人兴奋的发现，这可能是朝着有效管理神经系统健康问题迈出的离散一步。